Our client, a mid-sized biopharmaceutical company, aimed to introduce a new asset into the highly competitive Parkinson's disease category. Read the case study.
Explore scalable direct-to-patient (DTP) models that improve affordability, time-to-therapy, and patient engagement with a strategic, data-driven approach. Read here.
In July 2025, the Italian Medicines Agency (AIFA) revised its drug innovativeness criteria, ending “conditional” status and prioritizing rare and ultra-rare diseases. Read here.
Discover how Most Favored Nation (MFN) policy impacts U.S. drug pricing and market access in 2025, from CMS enforcement to launch planning. Get the whitepaper now.
A mid-size pharmaceutical company partnered with Herspiegel to establish a standing council of 30 patient advocates. This long-term engagement infused patient insights into strategic planning, enhancing relevance and trust across key functions. Read here.
At ISMPP 2025, a clear imperative emerged: the future of medical publications reporting must be more inclusive, accessible, and patient-centered. Read the article here.
Herspiegel’s Playbook for Navigating Loss of Exclusivity Through Commercial Levers provides pharmaceutical leaders with a comprehensive framework to address LOE strategically. Get the whitepaper now.
Patient Support Programs (PSPs) have become essential in bridging the gap between pharmaceutical companies and patients, ensuring access, affordability, and adherence to therapies. Get the whitepaper now.
We helped our client communicate key information about their portfolio and technology to help resonate with investors and support funding efforts. Read case study here.
We helped a client’s brand team improve patient adherence by mapping their access journey and identifying barriers and facilitators to patient access. Read the case study.
We helped a client’s brand team improve patient adherence by mapping their access journey and identifying barriers and facilitators to patient access. Read the case study.
Experts Ryan Subhan and Emily Phillips highlight early planning, market education, and overcoming challenges in launching rare disease therapies. Watch now.
This video highlights the challenges of launching an expensive therapy for a rare disease, focusing on partnerships, planning, and tailored care. Watch now.
The video highlights the crucial role of advocacy groups and the importance of early, strategic planning for successfully launching rare disease treatments. Watch now.
Our client was approaching the launch of a new product for treatment of a mental health disorder. Despite promising trial data, successful adoption of their therapy would be challenging for a number of reasons. Read the case study.
Discover how we assisted our client in positioning their therapy for optimal impact in the evolving landscape of steroid reduction and global treatment strategies.
Explore how we analyzed and refined our client's drug positioning across multiple indications to ensure market alignment and strategic coherence. Read the case study.
Our client aimed to apply a proven molecule to a new neurological disorder. We helped create a compelling narrative and cost-effective strategy to boost ROI. Read the case study.
Learn how we guided our client through early-stage clinical trials and competitive pressures to craft a compelling scientific narrative. Read the case study.
Learn how we navigated the challenges of launching a novel treatment in a rare hematologic disease to position our client's drug as a potential new standard of care. Read the full case study.
We helped our major pharmaceutical client equip it organization to offer value-based contracts to support access for a new specialty drug. Read the case study.
Discover how our tailored reimbursement strategy propelled a small biotech's innovative ophthalmic product to exceed launch forecasts by 60% in patient treatment.
We partnered with our client to establish a narrative that increased availability results in improvements in health outcomes and downstream cost savings. Read the case study.
We helped a client’s new product team plan their US and EU access strategies for a novel compound with potential in both rare and more common respiratory conditions. Read the case study.
Essential Strategies for Manufacturers to Adapt Financially and Operationally Amidst Evolving Regulatory Landscapes and Market Pressures. Read the article to find out more.
The Centers for Medicare & Medicaid Services (CMS) just announced the first set of drugs and biologics for price negotiations to be effective 2026. Read the article to find out more.
We helped a clinical-stage genetic medicine company enhance their manuscript and figures to meet the high standards of a top scientific journal. Discover how our targeted narrative refinement and figure enhancement led to their research being featured in a prestigious journal with an impact factor of 4.6.
Learn More
"*" indicates required fields
Herspiegel Principal
If you are looking for a leadership role shaping a growing practice, let’s talk.
Careers page, Principal profile
Herspiegel Managers
If you are looking to lead collaborative teams and build impactful relationships, let’s talk.
Careers page Manager profile
Herspiegel Consultant
If you are looking to apply your experience to deliver impactful solutions, let’s talk.
Herspiegel Analyst
If you are looking to build a career in the life sciences, let’s talk.
